Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial.

Rafii MS, Sol O, Mobley WC, Delpretti S, Skotko BG, Burke AD, Sabbagh MN, Yuan SH, Rissman RA, Pulsifer M, Evans C, Evans AC, Beth G, Fournier N, Gray JA, Dos Santos AM, Hliva V, Vukicevic M, Kosco-Vilbois M, Streffer J, Pfeifer A, Feldman HH.

Open source

DOI: 10.1001/jamaneurol.2022.0983
Published: 2022-06-01
Container: JAMA Neurol
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jamaneurol.2022.0983,
  title = {Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial.},
  author = {Rafii MS and  Sol O and  Mobley WC and  Delpretti S and  Skotko BG and  Burke AD and  Sabbagh MN and  Yuan SH and  Rissman RA and  Pulsifer M and  Evans C and  Evans AC and  Beth G and  Fournier N and  Gray JA and  Dos Santos AM and  Hliva V and  Vukicevic M and  Kosco-Vilbois M and  Streffer J and  Pfeifer A and  Feldman HH.},
  year = {2022},
  journal = {JAMA Neurol},
  doi = {10.1001/jamaneurol.2022.0983},
  url = {https://doi.org/10.1001/jamaneurol.2022.0983}
}

RIS

TY  - JOUR
TI  - Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial.
AU  - Rafii MS
AU  -  Sol O
AU  -  Mobley WC
AU  -  Delpretti S
AU  -  Skotko BG
AU  -  Burke AD
AU  -  Sabbagh MN
AU  -  Yuan SH
AU  -  Rissman RA
AU  -  Pulsifer M
AU  -  Evans C
AU  -  Evans AC
AU  -  Beth G
AU  -  Fournier N
AU  -  Gray JA
AU  -  Dos Santos AM
AU  -  Hliva V
AU  -  Vukicevic M
AU  -  Kosco-Vilbois M
AU  -  Streffer J
AU  -  Pfeifer A
AU  -  Feldman HH.
PY  - 2022
JO  - JAMA Neurol
DO  - 10.1001/jamaneurol.2022.0983
UR  - https://doi.org/10.1001/jamaneurol.2022.0983
ER  -

APA

MS, R., O, S., WC, M., S, D., BG, S., AD, B., MN, S., SH, Y., RA, R., M, P., C, E., AC, E., G, B., N, F., JA, G., AM, D. S., V, H., M, V., M, K., J, S., A, P., & HH., F. (2022). Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial.. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2022.0983

Source records

europe-pmc · retrieved 2026-09-26T08:33:05.875Z